Search - tctmd.com

Displaying 421 - 440 of 455

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2016

Shelley Wood

February 01, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Industry News

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

January 21, 2016

News Daily News

研究表明他汀类药物治疗会降低流感疫苗的有效性

Yael L. Maxwell

November 03, 2015

News Daily News

Statin Therapy Reduces Influenza Vaccine Effectiveness, Studies Suggest

Yael L. Maxwell

November 03, 2015

News Daily News

没有钱就得不到药物：全球范围内心血管疾病二级预防的障碍

Caitlin E. Cox

October 27, 2015

News Daily News

Sin Dinero Ni Medicamentos: Barreras Globales a la Prevención Secundaria de la Enfermedad Cardiovascular

Caitlin E. Cox

October 27, 2015

News Daily News

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Caitlin E. Cox

October 27, 2015

Presentation

Availability and Affordability of Cardiovascular Disease Medicines and Their Effect on Use in High-, Middle-, and Low-Income Countries

Presenter: R. Khatib

October 26, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Industry News

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

September 11, 2015

News Conference News ESC 2015

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Yael L. Maxwell

September 01, 2015

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

News Daily News

新型反义抑制剂能够降低高甘油三酯水平

August 13, 2015

News Daily News

Un Nuevo Inhibidor Antisentido Reduce los Niveles Altos de Triglicéridos

August 13, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Daily News

BARI 2D: El Mayor Control de los Factores de Riesgo en Pacientes con Diabetes Tipo 2 Mejora Supervivencia

Yael L. Maxwell

August 12, 2015

News Daily News

BARI 2D：改善 2 型糖尿病患者的危险因素控制情况可以提高其生存率

Yael L. Maxwell

August 12, 2015

News Daily News

钙化评分为零“保证”了无症状患者 15 年死亡率

August 06, 2015

Advertisement

TCTMD’s Top 10 Most Popular Stories for January 2016

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

研究表明他汀类药物治疗会降低流感疫苗的有效性

Statin Therapy Reduces Influenza Vaccine Effectiveness, Studies Suggest

没有钱就得不到药物：全球范围内心血管疾病二级预防的障碍

Sin Dinero Ni Medicamentos: Barreras Globales a la Prevención Secundaria de la Enfermedad Cardiovascular

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Availability and Affordability of Cardiovascular Disease Medicines and Their Effect on Use in High-, Middle-, and Low-Income Countries

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

新型反义抑制剂能够降低高甘油三酯水平

Un Nuevo Inhibidor Antisentido Reduce los Niveles Altos de Triglicéridos

Novel Antisense Inhibitor Cuts High Triglyceride Levels

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

BARI 2D: El Mayor Control de los Factores de Riesgo en Pacientes con Diabetes Tipo 2 Mejora Supervivencia

BARI 2D：改善 2 型糖尿病患者的危险因素控制情况可以提高其生存率

钙化评分为零“保证”了无症状患者 15 年死亡率

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content